Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 586 to 600 of 1561 results for do not do recommendations

  1. Does progesterone reduce the risk of preterm birth in women who have risk factors for preterm birth, but do not have a short cervix (cervical length of more than 25 mm)?

    Recommendation ID NG25/5 Question Does progesterone reduce the risk of preterm birth in women who have risk factors for preterm birth,

  2. Advance statements and decisions:- What forms of management of violence and aggression do service users prefer and do advance statements and decisions have an important role in management and prevention?

    Recommendation ID NG10/3 Question Advance statements and decisions:- What forms of management of violence and aggression do...

  3. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

    Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

  4. The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs (MIB159)

    NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .

  5. Supporting healthcare professionals to offer HIV tests:- What interventions are effective and cost effective to increase the likelihood of healthcare professionals offering and recommending an HIV test and of its subsequent uptake?

    Recommendation ID NG60/2 Question Supporting healthcare professionals to offer HIV tests:- What interventions are effective and cost...

  6. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)

    Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.

  7. Acute upper gastrointestinal bleeding in adults (QS38)

    This quality standard covers the management of acute upper gastrointestinal bleeding in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.

  8. Recognition of child sexual abuse:- What approaches to practice enable children (both boys and girls) who have been sexually abused to begin to tell practitioners about their experiences earlier, and in a way that does not contaminate the reliability of subsequent court proceedings?

    Recommendation ID NG76/1 Question Recognition of child sexual abuse:- What approaches to practice enable children (both boys and girls)

  9. Renal and ureteric stones (QS195)

    This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.

  10. Care of dying adults in the last days of life (QS144)

    This quality standard covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement.

  11. Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

    Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.

  12. moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment (HTG257)

    Evidence-based recommendations on moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment.

  13. Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)

    This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so

  14. End of life care for adults: service delivery (NG142)

    This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.

  15. Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)

    Evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer in adults.